Atul Bedi

CSO
Y-Trap

​​

Dr. Atul Bedi dovetails his expertise in tumor immunology with his clinical experience as a medical oncologist. As CSO of Y-Trap, he leads the scientific development of immuno-oncology therapeutics that arose from his translational cancer research program at Johns Hopkins University. Dr. Bedi’s work provided fundamental insights into the molecular mechanisms by which tumor cells evade immune surveillance and counteract death signals entrained by the immune system. His work has demonstrated that the antitumor efficacy of current tumor-targeted antibodies and immune checkpoint inhibitors is limited by the skewed differentiation of immune cell populations to immunoregulatory phenotypes via a cooperative network of specific cytokines in the tumor microenvironment. To address this therapeutic challenge, Dr. Bedi invented and developed a novel platform of targeted bifunctional immunomodulatory antibody-ligand traps that are designed to counteract the key cytokine determinants of these dysfunctional immune phenotypes. Multiple antibody-ligand traps from this platform are currently being advanced through clinical trials for immunotherapy of various treatment-refractory cancers. Dr. Bedi’s work has been published in Science, Nature Medicine, Nature Cell Biology, Nature Communications, Genes & Development, and Cancer Research. He has served on advisory committees for the National Cancer Institute (National Institutes of Health), as a member of the Experimental Therapeutics and Developmental Therapeutics Study Sections of the NCI, and the American Association for Cancer Research. Dr. Bedi also has an MBA in Life Sciences and Medical Services management from Johns Hopkins Carey Business School.